Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda’s Myeloma Drug Hopeful Ninlaro Rebuffed by CHMP
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion for Takeda Pharmaceutical’s hoped-to-be big-seller Ninlaro (ixazomib) for relapsed and/or refractory multiple myeloma. The company intends to challenge this decision to request…
To read the full story
Related Article
- Ninlaro Earns Conditional Approval in Europe: Takeda
November 25, 2016
- In a Turnaround, EU Panel Backs Takeda’s Ninlaro for Conditional Approval
September 21, 2016
- Takeda Gets CHMP’s Positive Opinion for New Adcetris Indication
May 31, 2016
BUSINESS
- Expert Calls for Greater Awareness of LC-FAOD after Dojolvi Debut
June 30, 2026
- Toho Defense Measure Scraped through Shareholder Vote: Report
June 30, 2026
- Enhertu Snags EU Approval in HER2 Positive Solid Tumors
June 30, 2026
- Datroway Grabs Positive CHMP Opinion in 1st-Line TNBC
June 30, 2026
- Tanabe Gets Thai Approval for Diabetes Drug Canalia
June 30, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…